Did regulators fail over selective serotonin reuptake inhibitors?
Healy
David
D
North Wales Department of Psychological Medicine, Cardiff University, Bangor LL57 2PW. healy_hergest@compuserve.com
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D015986:Confounding Factors, Epidemiologic; D003627:Data Interpretation, Statistical; D017277:Drug Approval; D005473:Fluoxetine / Q000009:adverse effects*; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects*; D018570:Risk Assessment / Q000592:standards; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013405:Suicide / Q000706:statistics & numerical data*; D014481:United States; D014486:United States Food and Drug Administration
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors